Phase I trial of IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics [0.03%]
针对复发性恶性胶质瘤的IL13Rα2导向的CAR-T细胞治疗I期临床试验:临床结果和药代动力学
Kiwan Kim,Seong-Won Song,Yeongha Jeon et al.
Kiwan Kim et al.
Purpose: This single-center, open-label, Phase 1 trial evaluated the safety and tolerability of chimeric antigen receptor (CAR)-T cells targeting interleukin-13 receptor α2 (IL13Rα2) in patients with malignant gliomas. ...
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial [0.03%]
循环胸苷激酶活性可预测SECOMBIT试验中BRAF突变型转移性黑色素瘤患者的生存期和最佳治疗顺序
Hildur Helgadottir,Mariaelena Capone,Laura Ridolfi et al.
Hildur Helgadottir et al.
Purpose: While immune checkpoint inhibitors (ICI) are generally the preferred first-line treatment for metastatic BRAF V600-mutated melanoma, a subgroup that remains incompletely defined requires initial tumor control wit...
Long-term results of multi-antigen stimulated cell therapy-I, alone or in combination with chemotherapy, as first-line maintenance therapy in advanced sarcoma: a multicenter, phase 1 trial [0.03%]
自体多抗原刺激的肿瘤浸润淋巴细胞静脉输注联合或不联合化疗作为软组织肉瘤一线维持治疗的Ⅰ期临床研究长期随访结果
Xing Zhang,Bushu Xu,Qiuzhong Pan et al.
Xing Zhang et al.
Purpose: Advanced sarcomas lack effective maintenance therapies after first-line chemotherapy. We present long-term phase 1 results evaluating multi-antigen stimulated cell therapy-I (MASCT-I), a novel immunotherapy integ...
Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies [0.03%]
乙酰辅酶a羧化酶抑制诱发内质网应激并增强抗癌药物疗效
Naing Lin Shan,Henriette Balinda,Jiawei Dai et al.
Naing Lin Shan et al.
Purpose: Increased dependence on de novo fatty acid synthesis is a key feature of metabolic rewiring in cancer cells. Acetyl-CoA-carboxylase (ACC) is the rate limiting enzyme of de novo fatty acid synthesis. We examined t...
Lewis Au,Jeanne Tie
Lewis Au
Circulating tumor DNA (ctDNA) profiling detects actionable genomic alterations in advanced biliary tract cancer faster (8 vs 27 days) and more often (90% vs 50%) than tissue, with high concordance. A recent retrospective study establishes c...
Phase I Trial of GPC3-Targeted TCR Fusion Construct, CT0180, in patients with Advanced Hepatocellular Carcinoma [0.03%]
GPC3靶向TCR融合构建体CT0180治疗晚期肝细胞癌的I期临床试验
Xuqi Sun,Wanwan Gao,Chunhui Shou et al.
Xuqi Sun et al.
Purpose: Treatment options for advanced hepatocellular carcinoma (HCC) remain limited, and responses to later-line therapies are modest. Glypican-3 (GPC3), highly expressed in HCC but rarely in normal tissues, is an attra...
Microsatellite Instability Identifies a Rare but Clinically Relevant Subset of Sarcomas: Insights from the Largest Clinically Sequenced Cohort with Therapeutic Implications [0.03%]
微卫星不稳定性确定了肉瘤中一个罕见但临床上重要的亚型:来自最大临床测序队列的治疗启示
Carla Saoud,Chad Vanderbilt,Jamal Benhamida et al.
Carla Saoud et al.
Introduction: Microsatellite instability (MSI) has broad biologic and clinical relevance across solid tumors, yet its role in sarcomas remains poorly defined. We delineate the clinicopathologic, molecular, and treatment-r...
Investigation of a prostate cancer radiation response signature in the breast cancer SweBCG91RT randomized trial [0.03%]
在乳腺癌SweBCG91RT随机临床试验中调查前列腺癌放射反应签名
Shuang G Zhao,Erik Holmberg,Dan Lundstedt et al.
Shuang G Zhao et al.
Purpose: PORTOS is a 24-gene radiation response signature developed and validated in multiple randomized trials in prostate cancer. Given its basis in general radiation and DNA damage response pathways, we sought to evalu...
Feasibility and activity of concurrent neoadjuvant chemotherapy and radiation therapy in patients with high-risk soft tissue sarcoma [0.03%]
高危软组织肉瘤患者同期新辅助化疗和放疗的可行性和活性
Elena Palassini,Sara Pizzamiglio,Emanuela Palmerini et al.
Elena Palassini et al.
Objective: The ISG-STS 1001 was an international, randomized, phase III, trial for localized, high-risk, STS comparing neoadjuvant ChT with epirubicin and ifosfamide (EI) versus a histology-tailored regimen. The trial inc...
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study [0.03%]
用于HRD阳性晚期卵巢癌新辅助治疗的奥拉帕利联合派姆单抗疗法:一项初步研究
Kenichi Harano,Takehiro Nakao,Shin Nishio et al.
Kenichi Harano et al.
Purpose: Preclinical studies suggest that poly(ADP-ribose) polymerase (PARP) inhibition enhances tumor immunogenicity through STING pathway activation, providing rationale for combination with immune checkpoint inhibitors...